In chronic atrial fibrillation the usual therapeutic target is the slowing of the ventricular response, but a return to sinus rhythm may offer considerable additional benefits to the patient.1 Most drugs used to suppress or prevent atrial fibrillation are inhibitors of the fast inward membrane current and tend to enhance atrioventricular conduction and are therefore usually given in combination with digoxin or other agents that slow conduction in the atrioventricular node. Amiodarone combines at antiarrhythmic effect in the atria with depression of atrioventricular conduction and is therefore useful in atrial fibrillation. As bepridil, introduced as an antianginal agent,2 3 has been shown to have electrophysiological properties-blocking both the slow4 5 and fast6 inward currents and prolonging repolarisation-it might thus be expected to Table 1 shows the clinical data of the fourteen patients in the study.
In four patients bepridil was withdrawn early because of the development of arrhythmias. In one case ventricular bigeminy was present at rest, while in three patients non-sustained uniform ventricular tachycardia developed on exercise (tables 2 and 3).
Four patients did not go on to receive amiodarone. One patient died of a pulmonary embolus, a second died of torsade de pointes during the third week on bepridil, and two others did not complete the study.
CONVERSION TO SINUS RHYTHM
Nine of fourteen patients were converted to sinus rhythm during bepridil: two in the first week, four in the second week, and three in the third week. Atrial fibrillation reappeared in all nine patients within eight days of discontinuing bepridil.
Four of ten patients were converted to sinus rhythm during amiodarone (six of these had converted during bepridil (NS)): one by one month, two by two months, and one other after four months (maintenance dose 200mg daily). Two of three patients remained in sinus rhythm when the amiodarone was reduced from 400 to 200mg daily, while the third reverted to atrial fibrillation; sinus rhythm resumed when the dose was restored to 400 mg daily.
Neither the cause nor the duration of atrial fibrillation were related to the successful restoration of sinus rhythm during bepridil (table 1). During Therefore, in deciding whether bepridil offers a real advance, the benefits must be weighed against the potential risks. Bepridil is certainly a powerful antiarrhythmic agent that offers much for the management of atrial fibrillation. But the QT, prolongation and arrhythmogenic effects are very worrying, particularly as the QT, interval can only be derived with any confidence, if at all, once sinus rhythm has been achieved. In atrial fibrillation, the QTc interval cannot be monitored as an early,warning sign. Thus, in our opinion, the risks outweigh the benefits and bepridil does not offer an appreciable advantage over the established regimens or amiodarone.
